An 18 F-labeled pyrazolo [1,5-a] 
Introduction
With the increasing availability of PET (positron emission tomography) to provide quantitative kinetic information of metabolic pathways and physiological processes in vivo [1] , PET and in particular an integrated PET/CT technique can detect diseases earlier and more accurately than any other imaging technique. A PET/CT is an effective tool to help to stage local, regional, distant diseases and to provide therapeutic guidance for cancer therapy. 2-[ 18 F]Fluoro-2-deoxyglucose ( 18 F-FDG), an analog of glucose, is the most widely used compound for cancer detection [2, 3] . In spite of being a very effective PET tracer for many types of tumors, with 18 F-FDG it is often difficult to differentiate tumor from inflammatory cells, especially for brain tumors because of the high background in the brain, and its low uptake in tumors that are growing slowly can cause false-negative results [4, 5] . Considering the drawbacks of using FDG for tumor imaging and the advantages of fluorine-18 as an ideal positron-emitting radionuclide (relatively longer half-life (110 min), comparable size to H atoms and lower energy), several new agents radiolabeled with 18 F that are under investigation or have found clinical use in cancer management [6] .
Pyrazolo [1,5-a] pyrimidine derivatives display extensive pharmaceutical activity due to the structural similarity of the pyrazolo [1,5-a] pyrimidine ring system to purine, and the latter exerts antimetabolic activity in biochemical reactions [7] . Furthermore, the pyrazolo[1,5-a]pyrimidine core structure has several positions for introducing a substituent, the C-5 and the C-7 position have commonly been used for introducing substituents in anti-tumor drug design [8 -13] . Recently, a series of novel 3-cyano-5,7-disubstituted pyrazolo [1,5-a] pyrimidine derivatives with various C-7 aniline substituents and C-5 amino alkoxy moieties have been synthesized and showed that pyrazolo [1,5-a] pyrimidine analogs of purine have strong anti-cancer activity [9] .
We set out to explore a radiolabeled analog of pyrazolo [1,5-a] pyrimidine for use as a PET tumor imaging agent. In this study, a novel 18 F-labeled pyrazolo [1,5- 
Results and Discussion

Chemistry
Scheme 1 shows the synthetic procedures for 5 and its 18 F-labeled analog ([ 18 F]5). The synthesis route to 1 followed a procedure described previously [9] . Substitution of 7-Cl in 1 with 2-chloroaniline produced 2. Treatment of 2 with ethylene glycol in DMF solution using NaH as a base generated 3. Direct interaction between 3 and toluene sulfonyl chloride provided the precursor 4. 19 F substitution to obtain 5 was achieved from precursor 4 using TBAF·3H 2 O in dry DMF at 100 • C under nitrogen atmosphere for 40 min with 30 % yield. The structure of 5 was characterized by 1 H NMR, 13 Fig. 2 .
Measurement of the partition coefficient
The partition coefficient (logP) value of [ 18 F]5 was 0.92, suggesting that this radiotracer is lipophilic.
Stability of [ 18 F]5 in vitro
The radio-HPLC showed that the radiotracer is stable in both phosphate-buffered saline (pH = 7.4) and murine plasma at 37 • C after 1 h.
Biodistribution of [ 18 F]5 in S180-bearing mice
The biodistribution data of [ 18 F]5 is summarized in Table 1 . Table 2 F]FET were taken from our previous report [14] . As shown in Table 1 , after a fast distribution, [ 18 F]5 was excreted from the body mainly through the liver and kidney. The radioactivity of [ 18 F]5 in the tumor was 2.18 ± 1.02, 3.66 ± 1.41, 2.83 ± 0.18, and 2.12 ± 0.53 % ID/g at 5, 15, 30, and 60 min postinjection (pi), respectively, showing a remarkably increasing uptake of this compound in the tumor. [ 18 F]5 reached its peak of 3.66 ± 1.41 % ID/g at 15 min pi, and then decreased to 2.12 ± 0.53 % ID/g after 60 min. Nearly 60 % radioactivity was still retained in the tumor after 60 min indicating good persistence in tumor uptake. Meanwhile, the radioactivity of [ 18 F]5 in other organs and tissues decreased rapidly. The tumor to brain, tumor to muscle and tumor to blood ratios reached high levels of 2.23, 1.14 and 1.30 at 15 min pi, respectively.
As shown in 
Conclusion
The new 18 F-labeled pyrazolo[1,5-a]pyrimidine derivative [ 18 F]5 was synthesized by nucleophilic substitution employing tosylate as leaving group and then purified by using reverse phase HPLC. The radiochemical purity of the product was higher than 98 % with radiochemical yields of 25 % (without decay correction). The biodistribution was studied in S180 
Experimental Section
All commercial reagents and solvents were used without further purification unless specified. Melting points were determined on an RY-1capillary tube apparatus without correction. 1 H NMR spectra were recorded on a Bruker (400 MHz) spectrometer. 13 C NMR and 19 F NMR spectra were recorded on a Bruker (100 MHz) spectrometer. Tetramethylsilane (TMS) was used as an internal standard. Chemical shift data of the proton resonances (δ ) were reported in parts per million relative to the internal standard TMS (δ = 0.0). Mass spectra were obtained using a Bruker Apex IV FTM instrument. Elemental analysis was performed with a Perkin-Elemer 240-C analyzer. IR data were obtained on a Nicolet 360 Avatar infrared spectrophotometer.
The [ 18 F]fluoride used for radiosynthesis was produced by the 18 O(p, n) 18 F nuclear reaction at the Center of Xuanwu Hospital (Beijing, China). Semipreparative HPLC purification was carried out using a semipreparative reversed-phase Grace Alltima TM C18 column (250 × 10 mm, particle size: 10 µm) under the indicated conditions. The semipreparative HPLC system used was an Alltech system with an Alltech HPLC pump Model 626, a Linear UVIS-201, and Bioscan flow-counter. Reversed-phase extraction Sep-Pak C18 Plus cartridges (Waters) were activated with methanol and water before use.
Synthesis of 5-(chloromethyl)-7-(2-chlorophenylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (2)
7-Chloro-5-(chloromethyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (1), shown in Scheme 1, was synthesized as described previously [9] . A solution of 1 (7.9 g, 35 mmol) in 2-propanol (5 mL) was mixed with 2-chloroaniline (4.7 mL, 45 mmol) and stirred at 60 • C for 3 h. After being cooled to room temperature, the precipitate was filtered, washed thoroughly with isopropanol, and then crystallized from methanol to produce product 2 (9. 
Synthesis of 7-(2-chlorophenylamino)-5-(2-hydroxyethoxymethyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (3)
To a solution of ethane-1,2-diol (0.24 mL, 4 mmol) in anhydrous DMF (5 mL) was added NaH (96 mg, 4 mmol). The suspension was stirred at ambient temperature for 10 min, and then 2 (32 mg, 1 mmol) was added. The mixture was heated at 50 • C for another 4 h, then cooled to room temperature and quenched by addition of H 2 O (5 mL). The solid was removed by filtration, and a saturated NaHCO 3 solution was added until no more colorless solid was formed. The colorless solid was collected by filtration and subjected to column chromatography on silica gel eluting with 
Synthesis of 2-((7-(2-chlorophenylamino)-3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)methoxy)-ethyl-4-methylbenzenesulfonate (4)
To a stirred solution of 3 (0.34 mg, 1 mmol) in CH 2 Cl 2 (20 mL) cooled with an ice bath (0 • C) was added Et 3 N (0.21 mL, 1.5 mmol), p-toluenesulfonyl chloride (TsCl, 0.29 g, 1.5 mmol) and a catalytic amount of 4-dimethylaminopyridine (DMAP, 0.03 g, 0.2 mmol). The reaction was continued at room temperature overnight after 30 min of incubation on ice. The volatile materials were evaporated under vacuum. The crude oily residue was further purified by column chromatography using petroleum ether 
Synthesis of 7-(2-chlorophenylamino)-5-((2-fluoroethyoxy)methyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (5)
Tetrabutylammonium fluoride trihydrate (TBAF . 3H 2 O, 0.63 g, 2 mmol) was dissolved in anhydrous CH 3 CN (1 mL) and heated rapidly at 120 • C under a nitrogen stream, followed by additional CH 3 CN (2 mL). The solvent was evaporated, and this process was repeated three times. After evaporating most of the solvent, a solution of 4 (0.50 g, 1 mmol) in anhydrous DMF (3 mL) was added to the dry reagent. The reaction mixture was stirred at 100 • C for 40 min under a nitrogen stream and cooled to room temperature, then diluted with H 2 O (20 mL) and extracted with ethyl acetate (10 mL × 3). The organic layer was dried over Na 2 SO 4 and concentrated in a vacuum to obtain a yellow oil. The residue was purified by silica gel chromatography using petroleum ether [1,5-a] 
Synthesis of 7-(2-chlorophenylamino)-5-((2-[ 18 F]fluoroethyoxy)methyl)-pyrazolo
Octanol/water partition coefficient
The partition coefficient was measured as previously described [14] . Each HPLC-purified radiotracer was added to a tube containing 0.5 mL of n-octanol and 0.5 mL of phosphate-buffered saline (pH = 7.4). Each phase had been presaturated with the opposite phase. The mixture was vortexed for 1 min and centrifuged at 15 000 rpm for 2 min. Aliquots of both phases were transferred in triplicate to counting tubes and assayed in a γ counter. The partition coefficient was calculated by dividing the radioactivity of the octanol layer by that of the water layer. This measurement was repeated three times.
Stability study
Each HPLC-purified radiotracer (3.7 MBq) was mixed with phosphate-buffered saline (pH = 7.4) at 37 • C for a period of up to 1 h and was analyzed by radio-HPLC. The stability of each HPLC-purified radiotracer in mouse plasma was determined by incubating 0.1 mL of the radiotracer (3.7 MBq) in the solution of 0.5 mL murine plasma at 37 • C for 1 h and 2 h. Plasma proteins were precipitated by adding acetonitrile and removed by centrifugation. The supernatant part was injected into radio-HPLC to determine the stability of the compound.
Biodistribution studies in S180 tumor-bearing mice
All the animal studies were carried out in compliance with relevant national laws relating to the conduct of animal experimentation. Uptake of [ 18 F]5 in Kunming Mice bearing S180 tumor models were performed according to published methods [14] .Briefly, S180 tumor cells were trypsinized, counted, and suspended in a solution containing DMEM and 10 % fetal bovine serum. The Kunming Mice were inoculated subcutaneously into the left forelimb with 5 × 10 6 tumor cells. Studies of tumor uptake were conducted when the tumors reached a size of 0.5 -0.8 cm in diameter. The tumorbearing mice were subjected to in vivo biodistribution and imaging studies.
Tissue biodistribution studies were conducted by administering, via the tail vein, a bolus injection of 370 kBq per mouse in a constant volume of 0.1 mL phosphate-buffered saline solution (pH = 7.4). The animals were sacrificed at 5, 15, 30 and 60 min post injection. The tissues and organs of interest were immediately collected, weighed and measured for 18 F radioactivity in a γ counter. Values are expressed as mean ± SD (n = 4).
